Nicolas Sommer

701 total citations
27 papers, 356 citations indexed

About

Nicolas Sommer is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Nicolas Sommer has authored 27 papers receiving a total of 356 indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Oncology, 12 papers in Cancer Research and 11 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Nicolas Sommer's work include Colorectal Cancer Treatments and Studies (20 papers), Cancer Genomics and Diagnostics (10 papers) and Cancer Treatment and Pharmacology (9 papers). Nicolas Sommer is often cited by papers focused on Colorectal Cancer Treatments and Studies (20 papers), Cancer Genomics and Diagnostics (10 papers) and Cancer Treatment and Pharmacology (9 papers). Nicolas Sommer collaborates with scholars based in United States, Switzerland and United Kingdom. Nicolas Sommer's co-authors include Herbert I. Hurwitz, Sarika Ogale, Johanna C. Bendell, Wendy Verret, Sairy Hernandez, Benjamin Tan, Riccardo Lencioni, Beiying Ding, John F. Palma and Alan Nicholas and has published in prestigious journals such as Journal of Clinical Oncology, Clinical Cancer Research and Annals of Oncology.

In The Last Decade

Nicolas Sommer

26 papers receiving 352 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Nicolas Sommer United States 11 260 107 107 74 70 27 356
Yong Mun United States 11 313 1.2× 79 0.7× 115 1.1× 50 0.7× 32 0.5× 43 464
Nisha L. Jacobs United States 6 201 0.8× 68 0.6× 77 0.7× 57 0.8× 37 0.5× 10 279
Richard M. Lee‐Ying Canada 10 168 0.6× 58 0.5× 125 1.2× 71 1.0× 57 0.8× 49 299
Jan-Henrik Terwey United Kingdom 8 264 1.0× 114 1.1× 104 1.0× 69 0.9× 68 1.0× 20 302
Hiroki Ikezawa Japan 11 300 1.2× 107 1.0× 116 1.1× 95 1.3× 60 0.9× 32 512
Aurélie Ferru France 11 250 1.0× 84 0.8× 82 0.8× 17 0.2× 86 1.2× 30 439
Jayne Gurtler United States 7 188 0.7× 82 0.8× 98 0.9× 120 1.6× 68 1.0× 14 332
Geoff Chong Australia 9 274 1.1× 111 1.0× 117 1.1× 37 0.5× 22 0.3× 25 414
Soetkin Vlassak Germany 6 239 0.9× 42 0.4× 127 1.2× 44 0.6× 33 0.5× 20 330
Nathalie Aucoin Canada 10 310 1.2× 46 0.4× 146 1.4× 23 0.3× 56 0.8× 29 348

Countries citing papers authored by Nicolas Sommer

Since Specialization
Citations

This map shows the geographic impact of Nicolas Sommer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Nicolas Sommer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Nicolas Sommer more than expected).

Fields of papers citing papers by Nicolas Sommer

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Nicolas Sommer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Nicolas Sommer. The network helps show where Nicolas Sommer may publish in the future.

Co-authorship network of co-authors of Nicolas Sommer

This figure shows the co-authorship network connecting the top 25 collaborators of Nicolas Sommer. A scholar is included among the top collaborators of Nicolas Sommer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Nicolas Sommer. Nicolas Sommer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Salem, Riad, Daneng Li, Nicolas Sommer, et al.. (2021). Characterization of response to atezolizumab + bevacizumab versus sorafenib for hepatocellular carcinoma: Results from the IMbrave150 trial. Cancer Medicine. 10(16). 5437–5447. 45 indexed citations
2.
Max, Xiaoju, Johanna C. Bendell, Herbert I. Hurwitz, et al.. (2020). Disease Monitoring Using Post-induction Circulating Tumor DNA Analysis Following First-Line Therapy in Patients with Metastatic Colorectal Cancer. Clinical Cancer Research. 26(15). 4010–4017. 19 indexed citations
3.
Desjardins, Annick, James E. Herndon, Frances McSherry, et al.. (2019). Single‐institution retrospective review of patients with recurrent glioblastoma treated with bevacizumab in clinical practice. Health Science Reports. 2(4). e114–e114. 11 indexed citations
4.
5.
Raghav, Kanwal, Shannon McDonough, Benjamin Tan, et al.. (2018). A randomized phase II study of trastuzumab and pertuzumab (TP) compared to cetuximab and irinotecan (CETIRI) in advanced/metastatic colorectal cancer (mCRC) with HER2 amplification: S1613.. Journal of Clinical Oncology. 36(15_suppl). TPS3620–TPS3620. 7 indexed citations
6.
Houts, Arthur C., Sarika Ogale, S. Yousuf Zafar, et al.. (2017). Progression-Free Survival in Patients Receiving Chemotherapy Alone (C) or Chemotherapy with Bevacizumab (CB) for First-Line Treatment of KRAS Mutant Metastatic Colorectal Cancer in Community Oncology Settings. Journal of Gastrointestinal Cancer. 50(1). 16–22. 5 indexed citations
7.
Johnston, Stephen S., Kathleen Wilson, Helen Varker, et al.. (2017). Real-world Direct Health Care Costs for Metastatic Colorectal Cancer Patients Treated With Cetuximab or Bevacizumab-containing Regimens in First-line or First-line Through Second-line Therapy. Clinical Colorectal Cancer. 16(4). 386–396.e1. 9 indexed citations
8.
González, Juan Marcos, Sarika Ogale, Robert Morlock, et al.. (2017). Patient and physician preferences for anticancer drugs for the treatment of metastatic colorectal cancer: a discrete-choice experiment. Cancer Management and Research. Volume 9. 149–158. 19 indexed citations
9.
Houts, Arthur C., Sarika Ogale, Nicolas Sommer, Sacha Satram‐Hoang, & Mark S. Walker. (2017). Treatment Patterns and Outcomes in Patients with KRAS Wild-Type Metastatic Colorectal Cancer Treated in First Line with Bevacizumab- or Cetuximab-Containing Regimens. Journal of Gastrointestinal Cancer. 50(1). 69–77. 15 indexed citations
10.
11.
Lee, John J., John F. Palma, Lijing Yao, et al.. (2017). Correlation of pre- and post-induction plasma mutant allele fraction with progression-free survival (PFS) in STEAM, a prospective, randomized, multicenter study in metastatic colorectal cancer (mCRC).. Journal of Clinical Oncology. 35(15_suppl). e15118–e15118. 1 indexed citations
12.
Johnson, Derek R., Antonio Omuro, Arliene Ravelo, et al.. (2017). Overall survival in patients with glioblastoma before and after bevacizumab approval. Current Medical Research and Opinion. 34(5). 813–820. 36 indexed citations
13.
Sinicrope, Frank A., Fang‐Shu Ou, Qian Shi, et al.. (2017). Randomized trial of FOLFOX alone or combined with atezolizumab as adjuvant therapy for patients with stage III colon cancer and deficient DNA mismatch repair or microsatellite instability (ATOMIC, Alliance A021502).. Journal of Clinical Oncology. 35(15_suppl). TPS3630–TPS3630. 31 indexed citations
14.
Johnson, Derek R., Antonio Omuro, Arliene Ravelo, et al.. (2016). Overall survival in patients with glioblastoma before and after bevacizumab approval.. Journal of Clinical Oncology. 34(15_suppl). 2062–2062. 5 indexed citations
15.
Houts, Arthur C., Sarika Ogale, Nicolas Sommer, & Mark S. Walker. (2016). Treatment patterns and outcomes in patients with KRAS wild type (WT) metastatic colorectal cancer (mCRC) treated in first line with bevacizumab (B) or cetuximab (C) containing regimens.. Journal of Clinical Oncology. 34(4_suppl). 550–550. 4 indexed citations
16.
17.
Morris, Van K., Filip Jankú, Helen J. Huang, et al.. (2015). Abstract A36: Circulating cell-free DNA as a marker for response and resistance to BRAF and EGFR inhibition in BRAF-mutated metastatic colorectal cancer. Molecular Cancer Therapeutics. 14(12_Supplement_2). A36–A36.
18.
González, Juan Marcos, Robert Morlock, Sarika Ogale, et al.. (2015). Patients' and physicians' risk-benefit trade-off preferences for metastatic colorectacl cancer treatments.. Journal of Clinical Oncology. 33(15_suppl). 3591–3591. 1 indexed citations
19.
20.
Belovich, Doris, et al.. (2009). Cost-effectiveness of capecitabine in combination with oxaliplatin (XELOX) compared with FOLFOX for the treatment of metastatic colorectal cancer: A Canadian evaluation. Journal of Clinical Oncology. 27(15_suppl). e17502–e17502. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Yong Mun Breakdown of academic impact, for papers by Nisha L. Jacobs Breakdown of academic impact, for papers by Richard M. Lee‐Ying Breakdown of academic impact, for papers by Jan-Henrik Terwey Breakdown of academic impact, for papers by Hiroki Ikezawa Breakdown of academic impact, for papers by Aurélie Ferru Breakdown of academic impact, for papers by Jayne Gurtler Breakdown of academic impact, for papers by Geoff Chong Breakdown of academic impact, for papers by Soetkin Vlassak Breakdown of academic impact, for papers by Nathalie Aucoin
Rankless by CCL
2026